NeoStem Welcomes Robert Dickey IV as Its New Chief Financial Officer
NEW YORK, Aug. 19, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS)
("NeoStem" or the "Company"), a leader in the emerging cellular therapy
market, announced today the appointment of Robert Dickey IV as Chief Financial
Officer. Mr. Dickey, an industry veteran as well as former investment banker,
is joining the Company effective today.Larry May, the Company's long-time
CFO, is assuming the newly-created position of Vice President, Strategic
Initiatives, and will assist Mr. Dickey in the transition as well as focus on
the Company's various strategic activities.
"I'm excited to join the superb team at NeoStem which now includes the
significant recent additions of Dr. Doug Losordo as Chief Medical Officer and
Mr. Stephen Potter as Executive Vice President," said Mr. Dickey. "In addition
to overseeing the financial function at the Company, I look forward to joining
Dr. Smith, the Company's dynamic Chairman and Chief Executive Officer, in
working to expand the Company's visibility in the marketplace with a focus on
institutional investors and evaluate, structure and assimilate new
opportunities in this rapidly growing industry that can further drive
shareholder value.I am thrilled to play a part in NeoStem's dedication to
strategic growth and its commitment to positively impact the world as cell
therapy heralds a new era in medical treatment."
"Rob has a truly impressive track record in the biotech and pharmaceutical
industries and is the ideal candidate to help the Company grow and add
shareholder value," said Dr. Robin L. Smith, Chairman and CEO of NeoStem."In
his prior roles, Rob has proven himself a key member of leadership teams
–driving finance, M&A, strategic deal making and business development. His
extensive, on-point experience will provide critical support for the
advancement of our development pipeline."
"I'm honored to have served the Company as CFO for many years and excited to
continue to serve in my new role," saidMr. May. "NeoStem's strategic
activities offer many opportunities and challenges and I hope my years of
experience with the Company and the pharmaceutical industry will continue to
support their execution. I look forward to collaborating with Robert as he
takes on the CFO role to help ensure a smooth transition for the Company."
Mr. Dickey has over 15 years of management experience at life sciences
companies, including positions as a CFO, COO and CEO and board member,
following a career as an investment banker. He has specific expertise in
financing, M&A, partnering/licensing transactions and project management, as
well as international experience. Mr. Dickey is joining NeoStem from
Hemispherx Biopharma, Inc. where he served as Senior Vice President.
Hemispherx is a publicly-traded company involved in immune-modulatory
therapies that is developing treatments for chronic fatigue syndrome and
influenza. Prior to Hemispherx , Mr. Dickey was Senior Vice President, Chief
Financial Officer and Business Unit Manager at StemCyte, Inc., an umbilical
cord stem cell therapeutics company. Other management experience includes
leadership positions at Protarga, Inc., a company developing cancer therapies,
and Locus Pharmaceuticals, a company involved in computational drug design.
Previously, he spent 18 years as an investment banker, 14 of those at Lehman
Brothers, with a background split between M&A and capital markets transactions
across a variety of industries. He earned an M.B.A from The Wharton School,
University of Pennsylvania, and an A.B. from Princeton University.
NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our
business model includes the development of novel proprietary cell therapy
products as well as operating a contract development and manufacturing
organization providing services to others in the regenerative medicine
industry. The combination of a therapeutic development business and
revenue-generating service provider business provides the Company with
capabilities for cost effective in-house product development and immediate
revenue and cash flow generation.
For more information, please visit: www.neostem.com.
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of this
press release, and involve certain risks and uncertainties. Forward-looking
statements include statements herein with respect to the successful execution
of the Company's business strategy, including with respect to consummating
strategic transactions in the cell therapy industry,performing the research
and development and clinical evaluation efforts in furtherance ofachieving
commercialization of cellular therapies, such as AMR-001, the future of the
regenerative medicine industry and the role of cellular therapy in that
industry and the Company's ability to successfully grow its contract
development and manufacturing business. The Company's actual results could
differ materially from those anticipated in these forward- looking statements
as a result of various factors. Factors that could cause future results to
materially differ from the recent results or those projected in
forward-looking statements include the "Risk Factors" described in the
Company's Annual Report on Form 10-K filed with the Securities and Exchange
Commission on March 11, 2013 and in the Company's periodic filings with the
SEC. The Company's further development is highly dependent on future medical
and research developments and market acceptance, which is outside its control.
Manager of Communications and Marketing
NeoStem Inc. Logo
Press spacebar to pause and continue. Press esc to stop.